Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The physiological role of rhomboid-like protein 4 in Alzheimer's disease pathology
FY 2017-18
Summary
A total of 36 million people worldwide is affected by Alzheimer's disease (AD), a debilitating neurodegenerative disease primarily characterized by worsening memory impairments as diseased stage advances. To date, no effective or preventative treatments are available meanwhile the number of patients is expected to rise in the next twenty years. Thus, AD imposes an increasing burden on the society. After many years of research, it is now clear that initial molecular changes underlying AD pathology occur 15 to 30 years before clinical symptoms arise. Gaining deeper insight into these molecular changes has therefore become imperative to develop new therapeutics that could intervene at the early, pre-symptomatic stage. One of the earliest biomarker to appear is the accumulation of amyloid-beta (Abeta) peptides in the brain, inducing neurotoxicity. However, Abeta-lowering therapies failed to produce clinically significant cognitive improvements in patients, suggesting that targeting these peptides alone may be insufficient to halt or delay the disease onset and progression. Other early molecular changes implicated in AD thus merit further investigation. Abeta is produced from sequential cleavage of the larger amyloid precursor protein (APP) by two classical proteases. Recently, our lab discovered a novel processing pathway for APP mediated by rhomboid-like protein 4 (RHBDL4), a member of an intramembrane protease family found in humans. This alternative APP processing gives rise to novel metabolites that may partly contribute to the phenotypic aberrations seen in AD. Consequently, this project aims to investigate the physiological relevance of the RHBDL4-APP pathway in AD in the hopes of identifying new therapeutic strategies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386327
Name
Recinto Sherilyn Junelle
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The physiological role of rhomboid-like protein 4 in Alzheimer's disease pathology
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Amyloid Precursor Protein; Cell Culture Experiments (In-Vitro Studies); Cloning; Immunocytochemistry/Immunohistochemistry; In-Vivo Studies; Intramembrane Proteolysis; Non-Amyloidogenic Pathways; Regulatory Mechanism; Rhomboid Protease; Western Blot
Abstract
A total of 36 million people worldwide is affected by Alzheimer's disease (AD), a debilitating neurodegenerative disease primarily characterized by worsening memory impairments as diseased stage advances. To date, no effective or preventative treatments are available meanwhile the number of patients is expected to rise in the next twenty years. Thus, AD imposes an increasing burden on the society. After many years of research, it is now clear that initial molecular changes underlying AD pathology occur 15 to 30 years before clinical symptoms arise. Gaining deeper insight into these molecular changes has therefore become imperative to develop new therapeutics that could intervene at the early, pre-symptomatic stage. One of the earliest biomarker to appear is the accumulation of amyloid-beta (Abeta) peptides in the brain, inducing neurotoxicity. However, Abeta-lowering therapies failed to produce clinically significant cognitive improvements in patients, suggesting that targeting these peptides alone may be insufficient to halt or delay the disease onset and progression. Other early molecular changes implicated in AD thus merit further investigation. Abeta is produced from sequential cleavage of the larger amyloid precursor protein (APP) by two classical proteases. Recently, our lab discovered a novel processing pathway for APP mediated by rhomboid-like protein 4 (RHBDL4), a member of an intramembrane protease family found in humans. This alternative APP processing gives rise to novel metabolites that may partly contribute to the phenotypic aberrations seen in AD. Consequently, this project aims to investigate the physiological relevance of the RHBDL4-APP pathway in AD in the hopes of identifying new therapeutic strategies.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Recinto, Sherilyn Junelle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~